1. New Zealand Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Pacific Edge Limited

Pacific Edge Limited

PFGTF
Pacific Edge LimitedUS flagOther OTC
0.17
USD
- -
- -
212.31MMarket Cap
Pacific Edge Limited
PFGTF
(Other OTC)

Recent

price

0.17

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
FRC
- -
- -
- -
- -
0.01
0.01
0.02
0.01
0.01
0.01
0.01
0.01
0.02
0.03
0.03
0.01
Revenue per Share
-0.02
-0.02
-0.02
-0.03
-0.03
-0.04
-0.05
-0.04
-0.03
-0.03
-0.02
-0.03
-0.03
-0.04
-0.04
-0.04
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.01
0.07
0.03
0.06
0.03
0.07
0.04
0.03
0.02
0.02
0.03
0.14
0.1
0.06
0.02
- -
Book Value per Share
0.01
0.07
0.03
0.07
0.03
0.08
0.05
0.03
0.03
0.02
0.03
0.14
0.1
0.07
0.03
0.01
Tangible Book Value per Share
208
262
320
337
345
387
410
466
514
581
714
768
810
811
812
945
Basic Weighted Avg Shares
- -
- -
- -
- -
2
5
8
3
4
4
8
11
20
24
22
11
Sales/Revenue/Turnover
-584,798.4
-48,059.53
-48,743.9
-6,937.73
-682.28
-359.64
-278.5
-630.74
-506.65
-453.91
-219.74
-193.85
-170.58
-153.85
-156.11
-339.71
Operating Margin (%)
- -
- -
- -
- -
- -
1
1
1
- -
1
- -
- -
1
3
2
2
Depreciation Expense
-3
-4
-7
-10
-11
-16
-21
-20
-18
-19
-14
-20
-27
-30
-30
-36
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-624,600
-42,412.9
-46,045.8
-6,853.54
-564.78
-315.07
-260.24
-577.76
-469.43
-432.17
-184.69
-172.9
-137.46
-123.54
-137.03
-311.14
Profit Margin (%)
4
17
10
20
10
29
20
26
21
26
42
106
78
50
21
7
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
2
1
- -
3
1
- -
LT Debt
3
18
11
22
12
30
21
17
14
15
25
108
83
55
26
11
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-162.53
-39.99
-47.94
-61.4
-67.59
-84.75
-96.3
-136.45
-177.13
-213.32
-96.67
-31.78
-29.67
-47.05
-90.32
-348.8
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.34%
32.52%
-59.14%
Free Cash Flow
29.45%
41.31%
-89.63%
Net Income, GAAP
10.52%
21.16%
19.51%
Sales/Revenue/Turnover
19.31%
17.18%
-47.36%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
24
2025
- -
- -
- -
- -
22
2026
- -
- -
- -
- -
11

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.04
2025
- -
- -
- -
- -
-0.04
2026
- -
- -
- -
- -
-0.04

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
ACS Global, Inc. (AMCY)
Medivolve Inc. (MEDV.NE)
Prenetics Global Limited (PRENW)
Quest Diagnostics Incorporated (0KSX.L)
Thermo Fisher Scientific Inc. (TMO)
Medivolve Inc. (4NC.F)
Business
Pacific Edge Limited (PFGTF), a cancer diagnostics company incorporated in 2001 and headquartered in Dunedin, New Zealand, develops and commercializes non-invasive genomic urine biomarker tests primarily for bladder cancer detection, risk stratification, and surveillance; its core Cxbladder product suite includes Cxbladder Triage, a frontline diagnostic for patients with hematuria to de-intensify cystoscopy in low-risk cases; Cxbladder Detect for risk stratification in hematuria patients; and Cxbladder Monitor as a non-invasive alternative to repeated cystoscopy for low-recurrence-risk patients previously diagnosed with bladder cancer. The company operates central laboratories in New Zealand and the United States, serving clinicians in these markets and internationally with a focus on urothelial cancer management; it also advances research and development for diagnostic products targeting gastric, colorectal, endometrial cancers, and melanoma. In 2025, Pacific Edge launched a NZ$20 million capital raise comprising a NZ$15 million placement to institutional investors and a NZ$5 million share purchase plan for retail investors, which closed with NZ$20.7 million in total new equity pledged to support testing volume growth, Medicare coverage challenges for Cxbladder Triage, clinical evidence generation for Triage Plus and Monitor Plus, and in vitro diagnostic kit development for decentralized international expansion.

Company News

APIChatGPT

  • seekingalpha.com

    Pacific Edge Limited (PFGTF) Q4 2026 Earnings Call Transcript